Evidence map›Paper›PMID 35141052›Full record

ArticleOncoimmunology2022

Immune sunrise: from the immunome to the cancer immune landscape.

Gabriela Bindea, Bernhard Mlecnik, Jérôme Galon

Abstract read
In one paragraph

Article in Oncoimmunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Stromal localization of inactive CD8British journal of cancer · 2024
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gabriela BindeaINSERM, Laboratory of Integrative Cancer Immunology, Paris, France.
Bernhard MlecnikINSERM, Laboratory of Integrative Cancer Immunology, Paris, France.
Jérôme GalonINSERM, Laboratory of Integrative Cancer Immunology, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The complex dynamics of the tumor-immune interaction during tumor progression have been characterized by integrating genomic and proteomic experiments. The Immunome, a reference compendium of markers for the majority of immune cell subpopulations was used to describe the immune landscape in cancer. The immune contexture is at the cornerstone in the success of cancer immunotherapies. Markers with the highest clinical relevance were summarized as the consensus immunoscore. This immune evaluation refines the prognosis of the patients and the chemotherapy decision-making process and was introduced as essential and desirable diagnostic criteria into three major international guidelines.

Indexed as

NeoplasmsProteomicsHumansImmunotherapyPrognosisTumor Microenvironmentchemotherapycolorectal cancerimmune landscapeimmunityimmunoscoreimmunotherapyprognosissurvivalT-cellstumor microenvironment

Identifiers

PMID35141052
PMCPMC8820808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.